Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst
admin 16th February 2018 Uncategorised 0Despite competitors’ efforts to pick up market share, an analyst figures J&J’s Remicade will dominate the market again in 2018.
More: Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst
Source: fierce